174 related articles for article (PubMed ID: 33299354)
1. Effective Inhibition of
Zhao Y; Li T; Tian S; Meng W; Sui Y; Yang J; Wang B; Liang Z; Zhao H; Han Y; Tang Y; Zhang L; Ma J
Cancer Manag Res; 2020; 12():12473-12485. PubMed ID: 33299354
[TBL] [Abstract][Full Text] [Related]
2. Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137.
Wang J; Sui Y; Li Q; Zhao Y; Dong X; Yang J; Liang Z; Han Y; Tang Y; Ma J
Cell Death Dis; 2020 Dec; 11(12):1029. PubMed ID: 33268769
[TBL] [Abstract][Full Text] [Related]
3. Dissecting super-enhancer driven transcriptional dependencies reveals novel therapeutic strategies and targets for group 3 subtype medulloblastoma.
Li M; Han Y; Wang C; Kang W; Jiang W; Zhang L; Tang Y
J Exp Clin Cancer Res; 2022 Oct; 41(1):311. PubMed ID: 36273157
[TBL] [Abstract][Full Text] [Related]
4. Characterization of an RNA binding protein interactome reveals a context-specific post-transcriptional landscape of MYC-amplified medulloblastoma.
Kameda-Smith MM; Zhu H; Luo EC; Suk Y; Xella A; Yee B; Chokshi C; Xing S; Tan F; Fox RG; Adile AA; Bakhshinyan D; Brown K; Gwynne WD; Subapanditha M; Miletic P; Picard D; Burns I; Moffat J; Paruch K; Fleming A; Hope K; Provias JP; Remke M; Lu Y; Reya T; Venugopal C; Reimand J; Wechsler-Reya RJ; Yeo GW; Singh SK
Nat Commun; 2022 Dec; 13(1):7506. PubMed ID: 36473869
[TBL] [Abstract][Full Text] [Related]
5. Triptolide and its pro-drug Minnelide target high-risk MYC amplified medulloblastoma in preclinical models.
Rodriguez-Blanco J; Salvador AD; Suter RK; Swiderska-Syn M; Palomo-Caturla I; Kliebe V; Shahani P; Peterson K; Turos-Cabal M; Vieira ME; Wynn DT; Howell AJ; Yang F; Ban Y; McCrea HJ; Zindy F; Danis E; Vibhakar R; Jermakowicz A; Martin V; Coss CC; Harris BT; de Cubas A; Chen XS; Barnoud T; Roussel MF; Ayad NG; Robbins DJ
J Clin Invest; 2024 Jun; ():. PubMed ID: 38885332
[TBL] [Abstract][Full Text] [Related]
6. Marinopyrrole derivative MP1 as a novel anti-cancer agent in group 3 MYC-amplified Medulloblastoma.
Coulter DW; Chhonker YS; Kumar D; Kesherwani V; Aldhafiri WN; McIntyre EM; Alexander G; Ray S; Joshi SS; Li R; Murry DJ; Chaturvedi NK
J Exp Clin Cancer Res; 2024 Jan; 43(1):18. PubMed ID: 38200580
[TBL] [Abstract][Full Text] [Related]
7. Targeted intervention of eIF4A1 inhibits EMT and metastasis of pancreatic cancer cells via c-MYC/miR-9 signaling.
Zhao Y; Wang Y; Chen W; Bai S; Peng W; Zheng M; Yang Y; Cheng B; Luan Z
Cancer Cell Int; 2021 Dec; 21(1):670. PubMed ID: 34906136
[TBL] [Abstract][Full Text] [Related]
8. Identification of Cardiac Glycosides as Novel Inhibitors of eIF4A1-Mediated Translation in Triple-Negative Breast Cancer Cells.
Howard CM; Estrada M; Terrero D; Tiwari AK; Raman D
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32759815
[TBL] [Abstract][Full Text] [Related]
9. Metabolism-based targeting of MYC via MPC-SOD2 axis-mediated oxidation promotes cellular differentiation in group 3 medulloblastoma.
Martell E; Kuzmychova H; Kaul E; Senthil H; Chowdhury SR; Morrison LC; Fresnoza A; Zagozewski J; Venugopal C; Anderson CM; Singh SK; Banerji V; Werbowetski-Ogilvie TE; Sharif T
Nat Commun; 2023 May; 14(1):2502. PubMed ID: 37130865
[TBL] [Abstract][Full Text] [Related]
10. Target-Based Screening against eIF4A1 Reveals the Marine Natural Product Elatol as a Novel Inhibitor of Translation Initiation with
Peters TL; Tillotson J; Yeomans AM; Wilmore S; Lemm E; Jiménez-Romero C; Amador LA; Li L; Amin AD; Pongtornpipat P; Zerio CJ; Ambrose AJ; Paine-Murrieta G; Greninger P; Vega F; Benes CH; Packham G; Rodríguez AD; Chapman E; Schatz JH
Clin Cancer Res; 2018 Sep; 24(17):4256-4270. PubMed ID: 29844128
[No Abstract] [Full Text] [Related]
11. Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas.
Oblinger JL; Burns SS; Akhmametyeva EM; Huang J; Pan L; Ren Y; Shen R; Miles-Markley B; Moberly AC; Kinghorn AD; Welling DB; Chang LS
Neuro Oncol; 2016 Sep; 18(9):1265-77. PubMed ID: 26951381
[TBL] [Abstract][Full Text] [Related]
12. OLIG2 Is a Determinant for the Relapse of MYC-Amplified Medulloblastoma.
Xu Z; Murad N; Malawsky D; Tao R; Rivero-Hinojosa S; Holdhof D; Schüller U; Zhang P; Lazarski C; Rood BR; Packer R; Gershon T; Pei Y
Clin Cancer Res; 2022 Oct; 28(19):4278-4291. PubMed ID: 35736214
[TBL] [Abstract][Full Text] [Related]
13. Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma.
Ecker J; Oehme I; Mazitschek R; Korshunov A; Kool M; Hielscher T; Kiss J; Selt F; Konrad C; Lodrini M; Deubzer HE; von Deimling A; Kulozik AE; Pfister SM; Witt O; Milde T
Acta Neuropathol Commun; 2015 Apr; 3():22. PubMed ID: 25853389
[TBL] [Abstract][Full Text] [Related]
14. A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma.
Chaturvedi NK; Kling MJ; Griggs CN; Kesherwani V; Shukla M; McIntyre EM; Ray S; Liu Y; McGuire TR; Sharp JG; Band H; Joshi SS; Coulter DW
Mol Cancer Ther; 2020 Jun; 19(6):1351-1362. PubMed ID: 32371591
[TBL] [Abstract][Full Text] [Related]
15. Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma.
Chaturvedi NK; Mahapatra S; Kesherwani V; Kling MJ; Shukla M; Ray S; Kanchan R; Perumal N; McGuire TR; Sharp JG; Joshi SS; Coulter DW
BMC Cancer; 2019 Nov; 19(1):1056. PubMed ID: 31694585
[TBL] [Abstract][Full Text] [Related]
16. Anti-proliferative activity of the quassinoid NBT-272 in childhood medulloblastoma cells.
von Bueren AO; Shalaby T; Rajtarova J; Stearns D; Eberhart CG; Helson L; Arcaro A; Grotzer MA
BMC Cancer; 2007 Jan; 7():19. PubMed ID: 17254356
[TBL] [Abstract][Full Text] [Related]
17. Improved therapy for medulloblastoma: targeting hedgehog and PI3K-mTOR signaling pathways in combination with chemotherapy.
Chaturvedi NK; Kling MJ; Coulter DW; McGuire TR; Ray S; Kesherwani V; Joshi SS; Sharp JG
Oncotarget; 2018 Mar; 9(24):16619-16633. PubMed ID: 29682173
[TBL] [Abstract][Full Text] [Related]
18. STAT3 Inhibition Attenuates MYC Expression by Modulating Co-Activator Recruitment and Suppresses Medulloblastoma Tumor Growth by Augmenting Cisplatin Efficacy In Vivo.
Rohrer KA; Song H; Akbar A; Chen Y; Pramanik S; Wilder PJ; McIntyre EM; Chaturvedi NK; Bhakat KK; Rizzino A; Coulter DW; Ray S
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190167
[TBL] [Abstract][Full Text] [Related]
19. Frondoside A Inhibits an MYC-Driven Medulloblastoma Model Derived from Human-Induced Pluripotent Stem Cells.
Xue Y; Fu Y; Zhao F; Gui G; Li Y; Rivero-Hinojosa S; Liu G; Li Y; Xia S; Eberhart CG; Ying M
Mol Cancer Ther; 2021 Jun; 20(6):1199-1209. PubMed ID: 33722850
[TBL] [Abstract][Full Text] [Related]
20. Assessing eukaryotic initiation factor 4F subunit essentiality by CRISPR-induced gene ablation in the mouse.
Sénéchal P; Robert F; Cencic R; Yanagiya A; Chu J; Sonenberg N; Paquet M; Pelletier J
Cell Mol Life Sci; 2021 Oct; 78(19-20):6709-6719. PubMed ID: 34559254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]